Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4-Reference-Cited by-同舟云学术

Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4

Published:2005-03-02 Issue:7 Volume:48 Page:2371-2387
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

VanderWel Scott N.¹,Harvey Patricia J.¹,McNamara Dennis J.¹,Repine Joseph T.¹,Keller Paul R.¹,Quin John¹,Booth R. John¹,Elliott William L.¹,Dobrusin Ellen M.¹,Fry David W.¹,Toogood Peter L.¹

Affiliation:

1. Department of Medicinal Chemistry, and Cancer Pharmacology, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm049355%2B

Reference87 articles.

1. The Hallmarks of Cancer

2. To cycle or not to cycle: a critical decision in cancer

3. Cancer Cell Cycles

4. CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors

5. CDK inhibitors: positive and negative regulators of G1-phase progression

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Potential Inhibitors of CDK1 by Integrating Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation Studies, and Evaluation of Their Inhibitory Activity;ACS Omega;2024-09-13

2. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

3. A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present;Expert Opinion on Therapeutic Patents;2024-07-17

4. Design, Synthesis of Novel Pyrido[2,3-d] pyrimidine Derivatives as SARS-CoV-2 Mpro Inhibitors for COVID-19 Therapy;Polycyclic Aromatic Compounds;2024-05-24

5. Recent Progress in CDK4/6 Inhibitors and PROTACs;Molecules;2023-12-13